<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697605</url>
  </required_header>
  <id_info>
    <org_study_id>CBGJ398X1101</org_study_id>
    <nct_id>NCT01697605</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Oral BGJ398 in Asian Patients</brief_title>
  <official_title>A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and tolerability to determine the Maximum tolerated dose
      (MTD) and/or Recommended dose (RD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398,
      administered on a continuous once and/or twice daily schedule.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2012</start_date>
  <completion_date type="Anticipated">December 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate and category of dose limiting toxicities (DLTs)</measure>
    <time_frame>First cycle of 28 days</time_frame>
    <description>Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of all Adverse Events (AEs) and Serious Advers Events (SAEs)</measure>
    <time_frame>From within 21 days of first treatment to 28 days after treatment discontinuation</time_frame>
    <description>To characterize the safety and tolerability of oral BGJ398</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hematology and chemistry values</measure>
    <time_frame>From baseline to 28 days after treatment discontinuation</time_frame>
    <description>hematology and chemistry values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of physical examinations, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Participants will be followed for the duration of treatment, an expected average of 24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time vs. concentration profiles</measure>
    <time_frame>1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks</time_frame>
    <description>To determine the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax, T1/2, etc) of oral BGJ398 including known pharmacologically active metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity</measure>
    <time_frame>Participants will be followed for the duration of treatment, an expected average of 24 weeks.</time_frame>
    <description>Assessed based on RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Participants will be followed for the duration of treatment, an expected average of 24 weeks.</time_frame>
    <description>Assessed by investigator per RECIST version 1.1. BOR is the best response recorded until disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Participants will be followed for the duration of treatment, an expected average of 24 weeks.</time_frame>
    <description>Assessed by investigator per RECIST version 1.1. ORR is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months.</time_frame>
    <description>PFS is defined as the times from the date of first dose of BGJ398 to the date of the first documented disease progression, date of death due to any cause or until a new anticancer therapy is initiated, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of all Adverse Events (AEs)</measure>
    <time_frame>From within 21 days of first treatment to 28 days after treatment discontinuation</time_frame>
    <description>To characterize the safety and tolerability of oral BGJ398</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Serious Advers Events (SAEs)</measure>
    <time_frame>From within 21 days of first treatment to 28 days after treatment discontinuation</time_frame>
    <description>To characterize the safety and tolerability of oral BGJ398</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all Adverse Events (AEs)</measure>
    <time_frame>From within 21 days of first treatment to 28 days after treatment discontinuation</time_frame>
    <description>To characterize the safety and tolerability of oral BGJ398</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all Serious Advers Events (SAEs)</measure>
    <time_frame>From within 21 days of first treatment to 28 days after treatment discontinuation</time_frame>
    <description>To characterize the safety and tolerability of oral BGJ398</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Tumor With Alterations of the FGF-R</condition>
  <arm_group>
    <arm_group_label>BGJ398</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398</intervention_name>
    <arm_group_label>BGJ398</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced solid tumors with FGF-R alteration

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients with untreated and/or symptomatic metastatic Central Nerve System (CNS)
             disease

          -  Pregnant or nursing (lactating) women

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East (NCEE)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

